TNF alpha-Mediated Loss of beta-Catenin/E-Cadherin Association and Subsequent Increase in Cell Migration Is Partially Restored by NKX3.1 Expression in Prostate Cells

WOS: 000343943700018PubMed ID: 25360740Inflammation-induced carcinogenesis is associated with increased proliferation and migration/invasion of various types of tumor cells. In this study, altered beta-catenin signaling upon TNF alpha exposure, and relation to loss of function of the tumor suppressor NKX3.1 was examined in prostate cancer cells. We used an in vitro prostate inflammation model to demonstrate altered sub-cellular localization of beta-catenin following increased phosphorylation of Akt((S473)) and GSK3 beta((S9)). Consistently, we observed that subsequent increase in beta-catenin transactivation enhanced c-myc, cyclin D1 and MMP2 expressions. Consequently, it was also observed that the beta-catenin-E-cadherin association at the plasma membrane was disrupted during acute cytokine exposure. Additionally, it was demonstrated that disrupting cell-cell interactions led to increased migration of LNCaP cells in real-time migration assay. Nevertheless, ectopic expression of NKX3.1, which is degraded upon proinflammatory cytokine exposure in inflammation, was found to induce the degradation of beta-catenin by inhibiting Akt((S473)) phosphorylation, therefore, partially rescued the disrupted beta-catenin-E-cadherin interaction as well as the cell migration in LNCaP cells upon cytokine exposure. As, the disrupted localization of beta-catenin at the cell membrane as well as increased Akt((S308)) priming phosphorylation was observed in human prostate tissues with prostatic inflammatory atrophy (PIA), high-grade prostatic intraepithelial neoplasia (H-PIN) and carcinoma lesions correlated with loss of NKX3.1 expression. Thus, the data indicate that the beta-catenin signaling; consequently sub-cellular localization is deregulated in inflammation, associates with prostatic atrophy and PIN pathology.Turkish Scientific and Technological Research Council (TUBITAK)Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [108S288, 210T066, 110S134, 113Z083]This research was granted by projects from Turkish Scientific and Technological Research Council (TUBITAK) 108S288 (COST_CANGENIN), 210T066 and 110S134 and 113Z083 to KSK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript